Mumbai, May 19 (PTI): Ranbaxy Laboratories on Friday said its US subsidiary Ranbaxy Pharmaceuticals Inc (RPI) has received tentative nod from United States Food and Drug Administration (USFDA) for manufacturing and marketing Fexofenadine Hydrochloride tablets, used in treatment of allergies.

"This product represents a future opportunity for Ranbaxy and will be launched following final approval from the FDA," RPI Vice President (Sales and Marketing) Jim Meehan said in a communique to the BSE.

The approval will allow Florida-based RPI, engaged in selling and distribution of generic as well as branded prescription products in US, to make and market the tablets in three dosages -- 30 mg, 60 mg and 180 mg.

Total annual market sales for Fexofenadine Hydrochloride Tablets were pegged at 931 million dollars and the nod will further expand the company's product portfolio of generic alternatives, Ranbaxy said.

Fexofenadine Hydrochloride is used for relieving symptoms of seasonal rhinitis like sneezing, rhinorrhea, itchy nose, throat, palate and eyes.